by regulating the level of expression and its timing. A regulated system to control protein expression has practical and, in some cases, essential roles for safe and effective therapeutic applications.

SUMMARY

[0001] In one aspect, there is provided a polynucleotide cassette for the regulation of the expression of a target gene comprising (a) a riboswitch and (b) an alternatively-spliced exon, flanked by a 5′ intron and a 3′ intron, wherein the riboswitch comprises (i) an effector region comprising a stem that includes the 5′ splice site of the 3′ intron, and (ii) an aptamer, wherein the alternatively-spliced exon comprises a stop codon that is in-frame with the target gene when the alternatively-spliced exon is spliced into the target gene mRNA. In one example, the aptamer specifically binds a small molecule ligand.

[0002] In one example, the polynucleotide for the regulation of the expression of a target gene ("gene regulation cassette" "regulatory cassette" or "polynucleotide cassette") contains 5′ and 3′ introns that are derived from an endogenous intron from the target gene. In one example, the 5′ and 3′ introns are exogenous to the target gene. In one example, the 5′ and 3′ introns are derived from intron 2 of the human β-globin gene. In one example, the 5′ intron comprises a stop codon in-frame with the target gene. In one example, the 5′ and 3′ introns are each independently from about 50 to about 300 nucleotides in length. In one example, the 5′ and 3′ introns are each independently from about 125 to about 240 nucleotides in length. In one example, the 5′ and/or 3′ introns have been modified to include, or alter the sequence of, an intron splice enhancer, an intron splice enhancer, a 5′ splice site, a 3′ splice site, or the branch point sequence.

[0003] In one example, the effector region stem of the riboswitch is about 7 to about 20 base pairs in length. In one example, the effector region stem is 8 to 11 base pairs in length.

[0004] In one example, the alternatively-spliced exon is derived from exon 2 of the human dihydrofolate reductase gene (DHFR), mutant human Wilms tumor 1 exon 5, mouse calcium/calmodulin-dependent protein kinase II delta exon 16, or SIRT1 exon 6. In one example, the alternatively-spliced exon is the modified DHFR exon 2 from SEQ ID NO:15. In one example, the alternatively-spliced exon has been modified in one or more of the group consisting of altering the sequence of an exon splice silencer, altering the

sequence of an exon splice enhancer, adding an exon splice enhancer, and adding an exon splice donor. In one example, the alternatively-spliced exon is synthetic (i.e., not derived from a naturally-occurring exon).

[0005] In another aspect, there is provided the polynucleotide cassette of the present invention for use in therapy. In another aspect, there is provided use of the polynucleotide cassette as described herein in the manufacture of a medicament for modulating the expression of a target gene, wherein (a) the polynucleotide cassette of the present invention (as, e.g., described above and herein) is to be inserted into the target gene, (b) the target gene comprising the polynucleotide cassette is to be introduced into a cell, and (c) the cell is to be exposed to a small molecule ligand that specifically binds the aptamer in an amount effective to induce expression of the target gene.

[0006] In one example, expression of the target gene is greater than about 5-fold higher when the small molecule ligand is present than the expression levels when the small molecule ligand is absent. In one example, the expression of the target gene is greater than about 10-fold higher when the small molecule ligand is present than the expression levels when the small molecule ligand is absent.

[0007] In one example, the polynucleotide cassette is inserted into the protein coding region of the target gene. In one example, two or more of the polynucleotide cassettes are inserted into the target gene. In one example, the two or more polynucleotide cassettes comprise different aptamers that specifically bind to different small molecule ligands. In another example, the two or more polynucleotide cassettes comprise the same aptamer of different aptamers that specifically bind the same ligand.

[0008] In one example, the target gene comprising the polynucleotide cassette is incorporated in a vector for the expression of the target gene. In one example, the vector is a viral vector. In further examples, the viral vector is selected from the group consisting of adenoviral vector, adeno-associated virus vector, and lentiviral vector.

[0009] In another aspect, there is provided use of a vector comprising a target gene that contains a polynucleotide cassette in the manufacture of a medicament for modulating expression of a target gene in the eye of a mammal wherein (a) the vector is to be introduced into the eye; and (b)

a ligand in an amount effective to induce expression of the target gene is to be provided to the mammal; wherein the polynucleotide cassette comprises (i) a riboswitch and (ii) an alternatively-spliced exon flanked by a 5′ intron and a 3′ intron, wherein the riboswitch comprises an effector region comprising a stem that includes the 5′ splice site of the 3′ intron, and an aptamer that binds a small molecule ligand, wherein the alternatively-spliced exon comprises a stop codon that is in-frame with the target gene. In one example, the ligand is a small molecule.

[0010] In one example, the vector is introduced into the eye by intraocular injection. In one example, the vector is a viral vector. In one example, the viral vector is selected from the group consisting of adenoviral vector, adeno-associated virus vector, and lentiviral vector.

[0011] In one example, the polynucleotide for the regulation of the expression of a target gene in the eye contains 5′ and 3′ introns that are derived from an endogenous intron from the target gene. In one example, the 5′ and 3′ introns are exogenous to the target gene. In one example, the 5′ and 3′ introns are derived from intron 2 of the human β-globin gene. In one example, the 5′ intron comprises a stop codon in-frame with the target gene. In one example, the 5′ and 3′ introns are each independently from about 50 to about 300 nucleotides in length. In one example, the 5′ and 3′ introns are each independently from about 125 to about 240 nucleotides in length. In one example, the 5′ and/or 3′ introns have been modified to include, or alter the sequence of, an intron splice enhancer, an intron splice enhancer, a 5′ splice site, a 3′ splice site, or the branch point sequence. In one example, the effector region stem of the riboswitch is about 7 to about 20 base pairs in length. In one example, the effector region stem is 8 to 11 base pairs in length. In one example, the alternatively-spliced exon is derived from exon 2 of the human dihydrofolate reductase gene (DHFR) mutant human Wilms tumor 1 exon 5, mouse calcium/calmodulin-dependent protein kinase II delta exon 16, or SIRT1 exon 6. In one example, the alternatively-spliced exon is the modified DHFR exon 2 from SEQ ID NO:15, a modified exon 2 from human DHFR. In one example, the alternatively-spliced exon has been modified in one or more of the group consisting of altering the sequence of an exon splice silencer, altering the sequence of an exon splice enhancer, adding an exon splice enhancer, and adding an exon splice donor. In one

example, the alternatively-spliced exon is synthetic (i.e., not derived from a naturally-occurring exon).

[0012] In one aspect, there is provided a recombinant polynucleotide comprising a target gene containing the polynucleotide cassette for regulating expression of the target gene (as, e.g., described above). In one example, the polynucleotide cassette is located in the protein coding sequence of the target gene.

[0013] In one aspect, there is provided a vector comprising a target gene that contains a polynucleotide cassette for regulating expression of the target gene (as, e.g., described above). In one example, the vector is a viral vector. In one embodiment, the viral vector is selected from the group consisting of adenoviral vector, adeno-associated virus vector, and lentiviral vector.

DESCRIPTION OF THE FIGURES

[0014] **Fig. 1a.** Schematic view of the splicing construct "Con 1" with the truncated human beta-globin intron 2 (IVS2Δ) inserted in the coding sequence of the luciferase gene. The designations "Luci Exon 1" and "Luci Exon 2" refer to the division of the luciferase gene into 5′ and 3′ coding sequences. Splicing of the inserted intron sequence IVS2Δ results in full length mRNA which is translated into full-length protein.

[0015] **Fig. 1b.** The effect of intron insertion and splice site sequence on luciferase expression. Con 1 through Con 7 have different intronic splice sites (*see* Table 1). Con 1 has IVS2Δ with its original IVS2 5′ splice site and 3′ splice site ("5'ss" and "3'ss" respectively). Con 2 to Con 7 have IVS2Δ inserted but with 5'ss and 3'ss sequence differences as listed in Table 1. Con 8 has no IVS2Δ intron. Con1 through Con 3 demonstrated no effects with intron insertion on luciferase expression compared to a luciferase control with no intron inserted (Con 8). Con 4 to Con 7, with weaker splice sites, displayed reduced luciferase expression.

[0016] **Fig. 2a.** Schematic diagram of the Intron-Exon-Intron cassette with exon inclusion (I) and exclusion (II) splicing patterns depicted. The star (✦) denotes a stop codon in DHFR exon 2. When the alternative DHFR exon is included in the target gene (luciferase) mRNA by splicing (I), the resulting transcript contains an in-frame stop codon, which blocks luciferase gene expression. Only when the alternative DHFR exon containing the stop codon is excluded from the final mRNA is the target gene expressed (II).

[0017] **Fig. 2b.** The effect of inclusion or exclusion of the DHFR alternative exon on expression of the luciferase gene. A luciferase assay was performed on HEK 293 cells transfected with different luciferase reporter constructs containing an Intron-Exon-Intron cassette as shown in Fig. 2a. The DHFR exon 2 with wild-type splice sites sequences (DHFR_wt) was compared to the DHFR exon containing mutations in the 5′ ss (DHFR_wt5ssC) or with the native 5' ss replaced with the stronger Con 1 5'ss

Claims:

1. A polynucleotide cassette for the regulation of the expression of a target gene comprising

    a. a riboswitch

    b. an alternatively-spliced exon, flanked by a 5′ intron and a 3′ intron,

    wherein the riboswitch comprises (i) an effector region comprising a stem that includes the 5′ splice site of the 3′ intron, and (ii) an aptamer,

    wherein the alternatively-spliced exon comprises a stop codon that is in-frame with the target gene when the alternatively-spliced exon is spliced into the target gene mRNA.

2. The polynucleotide cassette of claim 1, wherein the aptamer binds a small molecule ligand.

3. The polynucleotide cassette of claim 1 or 2 for use in therapy.

4. Use of the polynucleotide cassette of claim 1 or 2 in the manufacture of a medicament for modulating the expression of a target gene, wherein

    a. the polynucleotide cassette of claim 1 or 2 is to be inserted into a target gene,

    b. the target gene comprising the polynucleotide cassette of claim 1 or 2 is to be introduced into a cell, and

    c. the cell is to be exposed to a small molecule ligand that specifically binds the aptamer in an amount effective to induce expression of the target gene.

5. The use of claim 4, wherein the polynucleotide cassette is to be inserted into the protein coding region of the target gene.

6. The use of claim 4 or 5, wherein the expression of the target gene is greater than about 5-fold higher, or is greater than about 10-fold higher when the small molecule ligand is present than the expression levels when the small molecule ligand is absent.

7. The use of any one of claims 4-6, wherein two or more of the polynucleotide cassettes are to be inserted into the target gene, optionally

    wherein the two or more polynucleotide cassettes comprise different aptamers that specifically bind to different small molecule ligands, or

    wherein the two or more polynucleotide cassettes comprise the same aptamer.

8. The use of any one of claims 4 to 7, wherein the target gene comprising the polynucleotide cassette is to be incorporated in a vector for the expression of the target gene.

9. Use of a vector comprising a target gene that contains a polynucleotide cassette in the manufacture of a medicament for modulating expression of a target gene in the eye of a mammal, wherein:

a. the vector is to be introduced into the eye; and

b. a small molecule ligand in an amount effective to induce expression of the target gene is to be provided to the mammal;

wherein the polynucleotide cassette comprises (i) a riboswitch and (ii) an alternatively-spliced exon flanked by a 5′ intron and a 3′ intron, wherein the riboswitch comprises an effector region comprising a stem that includes the 5′ splice site of the 3′ intron, and an aptamer that binds a small molecule ligand, wherein the alternatively-spliced exon comprises a stop codon that is in-frame with the target gene.

10. The use of claim 9, wherein the vector is to be introduced into the eye by intraocular injection.

11. The use of claim 9 or 10, wherein the vector is a viral vector, optionally wherein the viral vector is selected from the group consisting of adenoviral vector, adeno-associated virus vector, and lentiviral vector.

12. The use of any one of claims 4 to 11, wherein the polynucleotide cassette is located in the protein coding sequence of the target gene.

13. The polynucleotide cassette of any one of claims 1 to 3, or the use of any one of claims 4 to 12, wherein the 5′ and 3′ introns

(i) are derived from an endogenous intron from the target gene;

(ii) are exogenous to the target gene; or

(iii) are derived from intron 2 of the human β-globin gene.

14. The polynucleotide cassette of any one of claims 1 to 3 and 13, or the use of any one of claims 4 to 13, wherein the 5′ intron comprises a stop codon in-frame with the target gene.

15. The polynucleotide cassette of any one of claims 1 to 3 and 13 to 14, or the use of any one of claims 4 to 14, wherein the 5′ and 3′ introns are each independently from about 50 to about 300 nucleotides in length, optionally

wherein the 5′ and 3′ introns are each independently from about 125 to about 240 nucleotides in length.

16. The polynucleotide cassette of any one of claims 1 to 3 and 13 to 15, or the use of any one of claims 4 to 15, wherein the effector region stem is about 7 to about 20 base pairs in length, optionally

wherein the effector region stem is 8 to 11 base pairs in length.

17. The polynucleotide cassette of any one of claims 1 to 3 and 13 to 16, or the use of any one of claims 4 to 16, wherein the alternatively-spliced exon

(i) is derived from exon 2 of the human dihydrofolate reductase gene, mutant human Wilms tumor 1 exon 5, mouse calcium/calmodulin-dependent protein kinase II delta exon 16, or SIRT1 exon 6;

(ii) has been modified by one or more of the group consisting of altering the sequence of an exon splice enhancer, altering the sequence of exon splice silencer, adding an exon splice enhancer, and adding an exon splice silencer;

(iii) is the modified DHFR exon 2 from SEQ ID NO:15; or

(iv) is synthetic.

18. A recombinant polynucleotide comprising a target gene containing the polynucleotide cassette of any one of claims 1 to 3 and 13 to 17, optionally

wherein the polynucleotide cassette is located in the protein coding sequence of the target gene.

19. A vector comprising a target gene that contains a polynucleotide cassette of any one of claims 1 to 3 and 13 to 17.

20. The vector of claim 19, wherein the vector is a viral vector, optionally

wherein the viral vector is selected from the group consisting of adenoviral vector, adeno-associated virus vector, and lentiviral vector.